Zim Laboratories (NSE:ZIMLAB) EBIT: ₹214 Mil (TTM As of Mar. 2026)


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
76 GF Score
Price ₹124.90
GF Value ₹102.87
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories EBIT?

Zim Laboratories NSE:ZIMLAB -2.32% 76 EBIT is ₹214 Mil as of Mar. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Zim Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹214 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zim Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 1.47%. Zim Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zim Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.81%.


Zim Laboratories  (NSE:ZIMLAB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zim Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=83.596 * ( 1 - 24.32% )/( (0 + 4317.455)/ 1 )
=63.2654528/4317.455
=1.47 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5393.871 - 798.397 - ( 278.019 - max(0, 1903.924 - 2758.085+278.019))
=4317.455

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zim Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=330.08/( ( (0 + max(0, 0)) + (2151.925 + max(1415.188, 0)) )/ 1 )
=330.08/( ( 0 + 3567.113 )/ 1 )
=330.08/3567.113
=9.25 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1090.38 + 937.748 + 451.224) - (798.397 + 0 + 265.767)
=1415.188

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zim Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=214.15/7618.002
=2.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zim Laboratories EBIT Related Terms


Zim Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories EBIT Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 282.12 403.25 295.24 282.56 202.89

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.18 8.72 28.16 94.76 82.52

NSE:ZIMLAB vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's EV-to-EBIT falls into.


NSE:ZIMLAB
76GF Score
Zim Laboratories Ltd NSE:ZIMLAB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹214 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹214 Mil mean?
Zim Laboratories (NSE:ZIMLAB) has a EBIT of ₹214 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zim Laboratories.
Is Zim Laboratories' EBIT too high?
Zim Laboratories' current EBIT is ₹214 Mil. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' EBIT compare to ZTS?
Zim Laboratories' EBIT of ₹214 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zim Laboratories. Zim Laboratories's current EBIT is ₹214 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current EBIT is ₹214 Mil. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current EBIT is ₹214 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • EBIT: ₹214 Mil
  • GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score

Get the complete analysis for NSE:ZIMLAB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.90
Price
₹102.87
GF Value